Home / Business and Economy / McKesson Stock: Strong Buy Amidst Growth Projections
McKesson Stock: Strong Buy Amidst Growth Projections
18 Jul
Summary
- McKesson stock has seen 17.5% growth in the past year.
- Analysts overwhelmingly recommend a 'Strong Buy' for MCK stock.
- Full-year earnings are projected between $43.80 and $44.60 per share.
McKesson Corporation, a prominent distributor of pharmaceuticals and medical supplies, is headquartered in Irving, Texas. The company, valued at $93.2 billion, operates across four key segments. In the past 52 weeks, MCK stock has appreciated by 17.5%, a performance slightly below that of the S&P 500 and the State Street Healthcare Select Sector SPDR ETF.
Following its Q4 2026 earnings release on May 7, MCK stock experienced a 1.5% increase. While quarterly revenue fell short of expectations, adjusted EPS exceeded forecasts. Looking ahead, analysts project fiscal 2027 EPS to reach $44.28, a 13.2% increase from fiscal 2025, with further growth expected in fiscal 2028.
Analysts maintain a highly favorable outlook on MCK, with 14 out of 18 covering the stock recommending a 'Strong Buy.' The average price target of $929.75 indicates a potential upside of 10.5%. McKesson anticipates full-year earnings in the range of $43.80 to $44.60 per share.
